Explore the evolving treatment landscape for Chronic Lymphocytic Leukemia, focusing on BTK and BCL2 inhibitor strategies and biomarker testing insights.
Back
Treatment of Chronic Lymphocytic Leukemia: Insights into BTK and BCL Inhibitor Sequencing
This program offers an in-depth, expert-driven exploration of the evolving treatment landscape for chronic lymphocytic leukemia (CLL), highlighting how targeted therapies are reshaping standards of care across frontline, relapsed, and refractory settings. Through panel discussion and analysis, leading clinicians examine the roles of covalent and non-covalent BTK inhibitors, venetoclax-based regimens, and the recently FDA-approved pirtobrutinib. The panel reviews emerging evidence for sequencing therapies, monitoring resistance, and incorporating time-limited approaches, as well as how patient-specific factors such as age, frailty, comorbidities, cytogenetics, and treatment history guide decision-making. Special emphasis is placed on real-world outcomes, retreatment considerations, MRD-guided strategies, and the future integration of cellular therapies, bispecific antibodies, and BTK degraders. The session also highlights practical co-management strategies between academic and community clinicians and identifies high-priority unmet needs, including Richter’s transformation and later-line therapeutic innovation.
Treatment of Chronic Lymphocytic Leukemia: Insights into BTK and BCL Inhibitor Sequencing
Episodes
All
All
Experts discuss evolving treatment strategies for CLL, highlighting the balance between time-limited and continuous therapies for optimal patient outcomes.
Experts discuss the importance of patient-specific factors and preferences in selecting first-line treatments for CLL.
Experts discuss the balance of safety, efficacy, and logistics in treatment choices, highlighting the evolving landscape of BTK inhibitors and patient preferences.
Experts discuss strategies for selecting second-line therapies in CLL, emphasizing treatment history, patient response, and genetic factors.
Experts discuss the implications of recent studies on pirtobrutinib, comparing its efficacy and safety against other BTK inhibitors for CLL treatment.
Explore the latest insights on venetoclax retreatment effectiveness and its impact on patient outcomes in chronic lymphocytic leukemia therapy.
Experts discuss the impact of real-world data on CLL treatment sequencing, highlighting survival outcomes and the importance of targeted therapies.
Experts discuss the role of MRD testing in CLL treatment, emphasizing personalized approaches and the importance of continuity in patient care.
Experts discuss advancements in CLL treatment, highlighting pirtobrutinib's role and the potential of CAR T-cells and bispecific therapies.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer
5